Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study

Aim: To evaluate the effectiveness and safety of anti-TNF drugs for ankylosing spondylitis. Materials & methods: A prospective cohort study was performed at a pharmacy in the Brazilian Public Health System. Effectiveness by Bath Ankylosing Spondylitis Disease Activity Index, functionality by Hea...

Descripción completa

Detalles Bibliográficos
Autores: Pedro Ricardokömel Pimenta, Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Adriana Maria Kakehasi, Francisco de Assis Acurcio, Juliana Alvares Teodoro
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:Brasil
Institución:Universidade Federal de Minas Gerais (UFMG)
Repositorio:Repositório Institucional da UFMG
Idioma:portugués
OAI Identifier:oai:repositorio.ufmg.br:1843/56515
Acceso en línea:https://becarispublishing.com/doi/10.2217/cer-2020-0275
http://hdl.handle.net/1843/56515
https://orcid.org/0000-0003-4024-0108
https://orcid.org/0000-0003-2550-7249
https://orcid.org/0000-0002-5528-0658
https://orcid.org/0000-0001-9411-7493
https://orcid.org/0000-0002-5880-5261
https://orcid.org/0000-0002-0210-0721
Access Level:acceso abierto
Palabra clave:Ankylosing spondylitis
Effectiveness
Observational study
Safety
Tumor necrosis factor inhibitors
Espondilite anquilosante
Eficacia
Inibidores
Descripción
Sumario:Aim: To evaluate the effectiveness and safety of anti-TNF drugs for ankylosing spondylitis. Materials & methods: A prospective cohort study was performed at a pharmacy in the Brazilian Public Health System. Effectiveness by Bath Ankylosing Spondylitis Disease Activity Index, functionality by Health Assessment Questionnaire Disability Index, quality of life by European Quality of Life Five-Dimensions and safety was assessed at 6 and 12 months of follow-up. Results: About 160 patients started the treatment with adalimumab, etanercept or infliximab. There was a statistically significant improvement in disease activity, functionality and quality of life at 6 and 12 months (p < 0.05). Conclusion: This real-world study has shown that anti-TNF drugs are effective and well tolerated for ankylosing spondylitis patients.